Overview

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation. PURPOSE: This randomized clinical trial is studying voriconazole to see how well it works compared to itraconazole in preventing fungal infections in patients who are undergoing allogeneic hematopoietic stem cell transplantation.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Hydroxyitraconazole
Itraconazole
Voriconazole
Criteria
DISEASE CHARACTERISTICS:

- Undergoing allogeneic hematopoietic stem cell transplantation

- No invasive yeast infection within the past 8 weeks

- Colonized or superficial infection allowed

- No documented or probable aspergillus or mold infection within the past 8 weeks

- Patients with a history of candidemia must have negative blood cultures and no
clinical signs of candidemia

PATIENT CHARACTERISTICS:

Age

- 12 and over

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No prior allergy or intolerance to imidazoles or azoles (e.g., fluconazole,
itraconazole, voriconazole, ketoconazole, miconazole, or clotrimazole)

PRIOR CONCURRENT THERAPY:

Biologic therapy

- See Disease Characteristics

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Other

- At least 1 week since prior amphotericin B or fluconazole for candidemia

- No concurrent therapy with any of the following:

- Rifampin

- Rifabutin

- Phenobarbital

- Phenytoin

- Carbamazepine

- Oral midazolam

- Triazolam

- Terfenadine

- Astemizole

- Concurrent topical antifungal agents for superficial fungal infections allowed